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Breast cancer is the leading causes of cancer-related death among women.The vast major-
ity of breast cancers are carcinomas that originate from cells lining the milk-forming ducts
of the mammary gland. Numerous articles indicate that breast tumors exhibit diverse phe-
notypes depending on their distinct physiopathological signatures, clinical courses, and
therapeutic possibilities.The human cytomegalovirus (HCMV) is a multifaceted highly host
specific betaherpesvirus that is regarded as asymptomatic or mildly pathogenic virus in
immunocompetent host. HCMV may cause serious in utero infections as well as acute
and chronic complications in immunocompromised individual.The involvement of HCMV in
late inflammatory complications underscores its possible role in inflammatory diseases and
cancer. HCMV targets a variety of cell types in vivo, including macrophages, epithelial cells,
endothelial cells, fibroblasts, stromal cells, neuronal cells, smooth muscle cells, and hepa-
tocytes. HCMV can be detected in the milk after delivery and thereby HCMV could spread
to adjacent mammary epithelial cells. HCMV also infects macrophages and induces an
atypical M1/M2 phenotype, close to the tumor-associated macrophage phenotype, which
is associated with the release of cytokines involved in cancer initiation or promotion and
breast cancer of poor prognosis. HCMV antigens and DNA have been detected in tissue
biopsies of breast cancers and elevation in serum HCMV IgG antibody levels has been
reported to precede the development of breast cancer in some women. In this review, we
will discuss the potential role of HCMV in the initiation and progression of breast cancer.
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INTRODUCTION
Breast cancer is the most frequent cause of cancer-related death
among women. According to world health organization more than
5 million deaths have been attributed to breast cancer in 2011
(Global Health Estimates, WHO 2013). Breast cancer represents a
heterogeneous disease. Based on the transcriptomic profile, breast
tumors have been categorized into at least five intrinsic subtypes (1,
2). These subtypes include basal like, ERBB2+, normal breast-like,
luminal subtype A, and B (1). Information regarding the intrinsic
subtype of breast cancer in patients has prognostic significance and
may help in designing personalized therapy in future (3). Familial
history of breast cancer, hormonal replacement therapies, alcohol
consumption, and radiation exposure are few risk factors associ-
ated with breast cancer (4). Biological entities especially viruses are
also known to trigger various cancers in human. There are at least
one dozen of viruses with established role in human malignancies
[comprehensively reviewed in Ref. (5)]. Few viruses are suspected
to play a role in the initiation or promotion of breast cancer (6).
One of such viruses is human cytomegalovirus (HCMV).
Human cytomegalovirus (also called human herpesvirus 5)
is a member of herpesviridae family (subfamily betaherpesviri-
nae). HCMV infects nearly 50–90% of the population worldwide.
HCMV infection is either asymptomatic or causes mild discom-
fort. In certain situations where immunity is either immature
or immunocompromised or suppressed, HCMV infection causes
significant morbidity and mortality (7, 8). In the last decade, pres-
ence of HCMV genome and antigens has been reported in several
kinds of human cancers. These human malignancies include breast
cancer, brain cancer, prostate cancer, colon cancer, and salivary
gland cancer (9, 10). In addition, we and others have shown the
oncogenic transforming potential of HCMV in vitro (11–13). In
this review, we will focus reader’s attention on the potential link
between HCMV infection and the initiation and/or development
of breast cancer.
HCMV AND BREAST CANCER: A VOLATILE RELATIONSHIP
Several attempts have been made to search for a virus responsi-
ble for breast cancer. In 1971, Moore and colleagues examined
the milk samples from women with or without the history of
breast cancer using electron microscopy. They found higher preva-
lence of virus like particles designated as “particle B” in the milk
of women with familial history of breast cancer. Exact nature of
“particle B” is still an enigma (14). With the rapid advancement
in DNA and protein technology, presence of several viruses has
been detected in breast cancer and normal tissue. The presence of
human papilloma virus (HPV) (15, 16), Epstein–Barr virus (EBV)
(17), human endogenous retroviruses (18), and more recently JC
and BK human polyomaviruses (19) has been reported in patients
www.frontiersin.org August 2014 | Volume 4 | Article 230 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Herbein and Kumar HCMV in breast cancer
derived breast cancer specimens (Table 1). However, contrasting
findings are also available, which make the relation of viruses and
breast cancer highly volatile.
Human cytomegalovirus has large protein repertoire that can
initiate or promote neoplastic changes in a cell. Richardson
hypothesized that incidence of breast cancer could be raised by
late exposure to HCMV (31). This hypothesis was based on the
incidence of breast cancer and its correlation with the seropreva-
lence of HCMV. Cox and colleagues investigated the correlation
between levels of HCMV IgG with the development of breast can-
cer. They enrolled 399 women with invasive breast cancer and 399
controls. Results of their study suggest a statistically significant cor-
relation with the elevation of HCMV IgG levels and development
of breast cancer in some women (22) (Table 2).
Breast milk is the predominant source of HCMV transmis-
sion in human. Presence of HCMV has been detected in more
than 90% of milk samples derived from women seropositive for
HCMV (32, 33). Using polymerase chain reaction and Southern
analysis, presence of HCMV DNA was reported in normal breast
tissue (34). Data from Cobb’s laboratory provide a more direct evi-
dence of breast epithelium as an important reservoir for HCMV in
humans. They detected the presence of HCMV antigens (specifi-
cally in glandular epithelium) in surgical biopsies of normal breast,
breast with tumor, and normal breast tissue from the breast can-
cer patients using immunohistochemistry. Prevalence of HCMV
Table 1 | A list of viruses that could potentially be involved in breast
cancer.
Virus Reference
Epstein–Barr virus (20, 21)
Human cytomegalovirus (22, 23)
Human papillomavirus (20, 24–26)
Simian virus 40 (27)
Human polyomavirus JC (19)
Human polyomavirus BK (19)
Human mammary tumor virus (28, 29)
Merkel cell polyomavirus (20)
Human endogenous retrovirus K (18, 30)
antigens was relatively higher in neoplastic epithelium of patients
with breast cancer (23).
A recent report by Soderberg-Naucler laboratory demonstrated
the presence of HCMV proteins and DNA in breast cancer and
sentinel lymph node metastases tissue using immunohistochem-
istry and PCR. In their study, presence of HCMV antigens was
restricted to metastatic tumor cells that are not consistent with
previous reports (23, 35).
There are several reports where no correlation has been found
between HCMV and breast cancer. For example, Antonsson and
coworkers screened for the presence of several viruses (including
HCMV and EBV) in 54 fresh breast tissue samples using real time
PCR. They did not detect the presence of HCMV in any sample
(20). In another instance, Utrera-Barillas and colleagues inves-
tigated the association of presence of HCMV DNA with breast
cancer progression in primary breast cancer biopsies using real
time PCR (36). They detected HCMV DNA in only 2 cases out of
27 breast cancer specimens. They found no significant correlation
between HCMV presence and breast cancer progression. Variation
in tissue handling, sample size, PCR primer designing, and sites of
tissue sampling could be responsible for the discrepancy in results
among different laboratories (37).
Collectively, data from in vitro and in vivo suggest that HCMV
may be involved in the initiation or progression of breast cancer.
However, in order to obtained conclusive results, clinical findings
need to be analyzed on large cohorts and in vitro findings need
further validation in animal models.
HCMV CELL TROPISM AND BREAST CANCER
Human cytomegalovirus is known to infect virtually most organs
of the human body including blood, brain, breast, colon, eye, kid-
ney, liver, and lung. Therefore, HCMV exhibits broader tropism.
Several reports indicate the replication of HCMV in various cells
ranging from monocytes to neural stem cells (23, 38–40). Mono-
cytes and macrophages are widely recognized as important HCMV
reservoirs responsible for the dissemination of the virus through-
out of the body (41, 42). Furthermore, infection of monocytes
by HCMV has potential to reprogram monocytes, resulting in
polarization toward inflammatory macrophages (M1) that also
exhibits properties of immunosuppressive macrophage (M2) (43)
(Figure 1). This polarization is mediated by induction of NF-κB
Table 2 | HCMV prevalence in breast cancer patients.
Study Subjects HCMV IgG
positivity (%)
Mean IgG HCMV DNA
positivity (%)
Reference
Sample I Sample IIc Seroconversion
1 Control women (n=399) 82.5 1.18 ODa 1.22 ODa n=3 np (22)
Invasive breast cancer patients (n=399) 78.7 1.09 ODa 1.19 ODa n=11 np
2 Non-inflammation breast cancer (n=49) 65 18.45±15.7 IU/mL (n=42) – 53.1b (46)
Inflammation breast cancer (n=28) 82 25.96±24.50 IU/mL (n=28) – 78.6b
aPositive control kit mean OD 0.825±0.110.
bStarting material was cancerous tissue.
cAverage time between two samples was 8.5 years in Ref (22).
n, number of patients, np, not performed.
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FIGURE 1 | Hypothetical scheme of HCMV dispersal and its possible
involvement in the development of breast cancer. Two potential scenarios
could ultimately result in breast tumor after HCMV infection. (1) HCMV that is
present in the milk could directly infect the mammary epithelial cells lining the
duct responsible for converting most precursors into milk constituents and
transporting them to the mammary lumen. Subsequently, macrophages
present in breast tissue could be also infected by HCMV favoring a protumoral
microenvironment. (2) HCMV present in blood (viremia) could infect
circulating monocytes. Upon migration of infected monocytes into breast
tissue, HCMV-infected macrophages could transmit the virus to mammary
epithelial cells. Additionally, monocytes/macrophages are regarded as a
prominent reservoir of HCMV infection. HCMV infection of
monocytes/macrophages can reprogram them to acquire M1/M2
characteristics. M1 macrophages secrete pro-inflammatory cytokines and M2
macrophages secrete immuno-suppressive factors that can promote the
progression of breast cancer. Tumor-associated macrophages (TAM) that are
of poor prognosis during breast cancer and fuel the progression of the
disease could be preferentially activated by HCMV.
and PI3K activities in monocytes upon HCMV infection (43). M1
macrophages secrete inflammatory factors including TNFalpha,
IL-6, and nitric oxide synthase 2 (Figure 1). Prolonged secretion
of these cytokines is often linked with the development of cancer
[reviewed in Ref. (44)]. We have also observed the positive cor-
relation among the seroprevalence of HCMV IgG, elevated IL-6
levels, and incidence of liver cancer in a patient oriented study
(45). In another instance, El-Shinawi and co workers investigated
the prevalence of HCMV infection in patients with inflamma-
tory breast cancer (IBC) and non-IBC invasive ductal carcinoma
(IDC) patients. They observed the higher prevalence of HCMV
IgG in patients with IBC than IDC patients (Table 2). Further-
more, they detected higher levels of DNA and activation of NF-κB
in cancerous tissue isolated from IBC as compared to IDC patients.
Increased activation of NF-κB can be a result of HCMV infection
of breast cells or indirectly by cytokine production in the tumor
microenvironment (46).
Macrophages associated with the tumorous environment are
known as tumor-associated macrophages (TAM). The predomi-
nant fractions of TAMs are M2 polarized macrophages. Upon infil-
trating tumor surroundings of breast cancer cells, macrophages
may acquire M2 state. These M2 macrophages secrete high levels
of immunosuppressive cytokines, e.g., IL-10, TGF-beta, and little
amount of pro-inflammatory cytokines [reviewed in Ref. (47)]
(Figure 1). These M2 macrophages being immunosuppressive in
nature indirectly favors the development of breast cancer. Since
HCMV can infect normal breast and malignant breast tissue
therefore the role of HCMV in favoring TAMs phenotype (by
inducing M2 polarization) and breast cancer progression is highly
speculated. For instance, the clinical isolate HCMV-DB displays
preferential macrophage tropism, triggers M2 activation state, and
stimulates the upregulation of the proto-oncogene Bcl-3 (38).
Indeed, TAMs are considered as an important therapeutic
target in breast cancer. Luo and colleagues have identified legu-
main a stressed molecule overexpressed by TAMs. In addition, the
application of DNA vaccine against legumain has been shown to
dramatically reduce tumor angiogenesis in animal model (48).
Taken together, these primarily data suggest that the potential
route of viral dispersal to breast tissue and involvement of HCMV
in breast cancer progression.
POTENTIAL ONCOGENES IN HCMV GENOME
Human cytomegalovirus is a double stranded DNA virus with
~240 kb of genomic information. Recent study reveals the presence
of more than 700 translated ORFs (49) in HCMV genome, which
is more than double of previous predictions (50, 51). HCMV
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FIGURE 2 | Overview of diverse HCMV proteome involved in modulation of host cell controlled growth.
gene products have been reported to be involved in cell cycle
dysfunction, genome instability, cell immortalization, inhibition
of important cellular players involved in apoptosis and immune
invasion (52–55) (Figure 2).
Several members of HCMV proteome have oncogenic prop-
erties. For instance, stable expression of US28 in NIH3T3 cells
has been shown to induce transformed phenotypes. In addition,
injection of NIH3T3 cells stably expressing US28 in mice leads
to tumor formation (56). One of the responsible mechanisms for
induction of tumor growth could be the activation of IL6–JAK1–
signal transducer and activator of transcription 3 (STAT3) axis by
US28 in vitro and in vivo (57). Furthermore, we have also observed
similar findings in primary human hepatocytes and HepG2 cells
upon HCMV infection (13).
Other gene products with oncogenic potential are immediate
early (IE) 1 and IE2. Shen and colleagues have observed the trans-
formation of primary baby rat kidney (BRK) cells upon transient
expression of IE1, IE2, and adenovirus E1A proteins. Interestingly,
they were not able to detect the presence of IE1/IE2 DNA in clonal
cell lines derived from transformed BRK foci. The unconventional
“hit and run” mechanism has been proposed to explain the trans-
formation by IE1/IE2 (58). In addition, ectopic expression of IE1
induces telomerase mRNA and enhance telomerase activation in
normal human diploid fibroblasts in vitro (59) (Figure 2).
Purified HCMV virions have reported to induce chromosomal
breaks in primary human foreskin fibroblasts (HFF) (60). Data
from Spector laboratory further revealed that only viral entry but
not viral gene expression was prerequisite to induce chromosomal
breaks in HFF (60). UL76 (one of the virion associated proteins)
stable expression in human glioblastoma cells has been shown to
induce chromosomal breaks (61) (Figure 2).
Taken together, data suggest that the presence of several HCMV
proteins that have ability to induce transformation. Of note, tran-
sient or stable expression of a particular viral gene may not truly
represent the natural HCMV infection scenario. Rigorous exper-
imentations are needed to elucidate the exact function of these
viral proteins in tumor tissue.
ANTIVIRAL DRUGS AGAINST HCMV AS NOVEL BREAST
CANCER THERAPIES
Presence of HCMV in various cancerous tissues raises the pos-
sibility of using anti-HCMV drugs in targeting cancer cells. In
breast cancer and HCMV infection, there are several common
pathways that are activated. For example, aberrant activity of
STAT3, PI3K, NF-κB, MAPK, and Wnt driven cascade is observed
in both HCMV infection and breast cancer (Table 3). Therefore,
drugs that target these pathways should have significant impact on
both HCMV infection and tumor progression. There are several
compounds at preclinical or clinical trial stage that show sig-
nificant impact on cancer development (Table 3). One of such
FDA approved drug is sorafenib, a multi kinase inhibitor that
affects several signaling cascades. Sorafenib is known to inhibit
the replication of HCMV in several cell types in vitro (62).
In addition, sorafenib inhibits cell death and induce apoptosis
in several breast cancer cell lines including MCF-7 and MDA-
MB-231 (63). In a phase II clinical trial involving patients with
HER2 negative breast cancer, combination of sorafenib and cepac-
itabine has been reported to improved progression free survival
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Table 3 | Major signaling pathways targeted by HCMV and activated in
breast cancer.
Signaling pathways
altered upon HCMV
infection
Effector
viral
protein
Drugs/inhibitors
targeting signaling
pathways in breast
cancer
Reference
JAK-STAT3 US28, IE1 Sorafenib (57, 66, 67)
FLLL31a, FLLL32a,
BP-1-102a
(68, 69)
PI3K-AKT IE1, IE2 Buparlisib (BKM120)b (70, 71)
NVP-BEZ235a (72, 73)
MK-2206b (74)
MAPK-ERK gB Sorafenib (75–79)
CI-1040 (PD184352)b (80)
Wnt/beta-catenin Not known XAV939a (81, 82)
aPreclinical stage.
bIn clinical trial.
in patients (64). Furthermore, phase III clinical trial (Clinicaltri-
als.gov, NCT01234337) with reduced dose of sorafenib has been
also started (65).
Signal transducer and activator of transcription 3 is an impor-
tant transcription factor that governs genes responsible for
cell cycle progression and apoptosis. Upregulation of pSTAT3
has been reported in several kinds of malignancies includ-
ing breast cancer (83). In addition, activation of IL6–JAK–
STAT3 axis has been observed upon HCMV infection in sev-
eral cell types (13, 57). Involvement of viral proteins IE1 and
US28 in modulating this signaling axis has been suggested (57,
66) (Table 3). Moreover, recent work demonstrates the acti-
vation of STAT3 in a triple negative breast cancer cell line
(MDA-MB-231) upon treatment of cmvIL-10 (84). cmvIL-10
is encoded by ORF UL11a and is homolog to human IL-10
(85). Furthermore, exposure of cmvIL-10 to these breast cancer
cell lines resulted in increase in cell proliferation and decrease
in apoptosis.
Lin and colleagues designed two inhibitors designated as
“FLLL31” and “FLLL32” derived from curcumin. These inhibitors
bind specifically to Janus kinase 2 and STAT3 Src homology-2
domain that are indispensable for STAT3 dimerization and down-
stream signal transduction (68). In vitro application of these
inhibitors has shown to inhibit STAT3 activation, cell invasion,
and colony formation in breast cancer cell lines (68). Even results
were promising in animal models. Same group has recently devel-
oped another STAT3 inhibitor termed BP-1-102 that represses the
tumor growth of breast cancer cells in xenografts (69).
Another important signaling axis pertaining to homeostasis
is PI3K–Akt axis. PI3K driven signaling cascades play an impor-
tant role in cell growth, differentiation, glucose metabolism, and
chemotaxis (86). In breast cancer, aberrant expression of PI3K and
its downstream signaling partners is frequently observed. Involve-
ment of IE1 and IE2 in activation of PI3K pathway has been also
suggested (70). Several PI3K inhibitors are being tested against
various cancers including breast cancer in clinical trials (Table 3).
However, impact of these inhibitors in HCMV replication is not
assessed.
In addition to above mentioned signaling pathways, impact
of HCMV infection on Wnt pathway has been investigated (81,
87). HCMV-infected fibroblasts and human placental extravil-
lous trophoblasts (81) exhibited decreased levels of Wnt 5a/b, Wnt
driven beta-catenin, and total as well as phosphorylated form of
lipoprotein receptor related protein 6 (87). In addition, treatment
of cells with Wnt modulators (monensin, nigericin, and salino-
mycin) resulted in inhibition of HCMV replication in fibroblasts,
suggesting important role of Wnt signaling partners in HCMV
replication. Wnt plays important role in cell growth, cell fate deter-
mination, and tumorigenesis. Upregulation of Wnt pathway genes
have been observed in breast cancer cell lines and patient samples
(88). Collectively, this makes Wnt pathways an attractive tool in
targeting HCMV and breast cancerous cells simultaneously. For
example, XAV939 a small molecule tankyrase inhibitor has been
shown to attenuate Wnt pathways in several breast cancer cell
lines (82). However, effect of XAV939 in HCMV replication is
not known yet and needs further investigations. Development
of resistance against a particular drug during cancer progres-
sion is frequent. Therefore, there is need to formulate feasible
combinatorial therapies against breast cancer.
CONCLUSION
Several clinical and experimental investigations suggest the
involvement of HCMV in various malignancies including breast
cancer. In vitro and animal models suggest the presence of potent
oncogenes genes in HCMV genome. Significance of higher preva-
lence of HCMV in breast cancer tissue is poorly understood.
Whether it is just an “epiphenomenon” or crucial player in the
progression of cancer needs further investigations.
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